Low grade serous ovarian cancer – A rare disease with increasing therapeutic options

Tibor A. Zwimpfer,Ori Tal,Franziska Geissler,Ricardo Coelho,Natalie Rimmer,Francis Jacob,Viola Heinzelmann-Schwarz

Cancer Treatment Reviews（2022）

引用 2|浏览9

暂无评分

摘要

•LGSOC and HGSOC should be seen and treated as distinct ovarian cancer subtypes.•LGSOC has a chemo-resistant nature and optimal treatment has not yet been defined.•ER, KRAS, BRAF, CDK 4/6 and MAPK represent critical targets in LGSOC therapy.•Endocrine treatment, MEK and BRAF inhibitors are promising treatment options.•Results from ongoing clinical trials will probably change treatment regimens.

查看译文

关键词

ER,KRAS,CDK 4/6,MEK inhibitors,BRAF inhibitors,Endocrine treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要